doxorubicin + etoposide + prednisone

This is a combination chemotherapy regimen consisting of three drugs—doxorubicin, etoposide, and prednisone. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of replication. - **Etoposide** is a topoisomerase II inhibitor that causes DNA damage by preventing the religation of double-stranded breaks induced during DNA replication. - **Prednisone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties; in cancer therapy, it induces apoptosis in certain malignant lymphoid cells. This combination has been studied as part of multi-agent regimens (such as CHEP or CHOEP) for aggressive non-Hodgkin lymphoma (NHL), T-cell lymphomas, and other hematologic malignancies[1][5]. The rationale for combining these agents lies in their complementary mechanisms targeting rapidly dividing cancer cells through different pathways.